<code id='70F3977399'></code><style id='70F3977399'></style>
    • <acronym id='70F3977399'></acronym>
      <center id='70F3977399'><center id='70F3977399'><tfoot id='70F3977399'></tfoot></center><abbr id='70F3977399'><dir id='70F3977399'><tfoot id='70F3977399'></tfoot><noframes id='70F3977399'>

    • <optgroup id='70F3977399'><strike id='70F3977399'><sup id='70F3977399'></sup></strike><code id='70F3977399'></code></optgroup>
        1. <b id='70F3977399'><label id='70F3977399'><select id='70F3977399'><dt id='70F3977399'><span id='70F3977399'></span></dt></select></label></b><u id='70F3977399'></u>
          <i id='70F3977399'><strike id='70F3977399'><tt id='70F3977399'><pre id='70F3977399'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:98891
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          NIH tests clinical research in primary care with $30 million program
          NIH tests clinical research in primary care with $30 million program

          TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          How the BIOSECURE Act is already affecting U.S., Chinese life science firms

          ARIANADREHSLER/AFPviaGettyImagesSANDIEGO— U.S.legislationthatseekstorestrictAmericanbiotechsfromwork